

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT AMBROXOL HYDROCHLORIDE INJECTION PASSED CONSISTENCY EVALUATION

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for Ambroxol Hydrochloride Injection (including 4ml:30mg, 2ml:15mg and 1ml:7.5mg) of Shijiazhuang No. 4 Pharmaceutical Co., Ltd., a wholly subsidiary of the Company.

Ambroxol Hydrochloride Injection is under previous type 6 chemical drug. It is used in mucus clearance treatment of acute and chronic lung diseases accompanied by abnormal sputum secretion and poor sputum excretion (such as acute exacerbation of chronic bronchitis, wheezing bronchitis and bronchial asthma), and is also used in preventive treatment of lung complications after surgery etc.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 30 December 2020

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.